https://clinicaltrials.gov/ct2/show/NCT01422694
Mar 27th, 2023 - The purpose of this protocol is to study the natural history of spondyloarthritis (SpA) in children and adults. Spondyloarthritis encompasses a spectrum of immune-mediated inflammatory diseases that exhibit overlapping features, but differ from other types of inflammatory arthritis in genetic predisposition, pathogenesis, and outcome. Ankylosing spondylitis (AS), the most common form of SpA, fr...
https://clinicaltrials.gov/ct2/show/NCT04436640
Mar 31st, 2023 - The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
https://clinicaltrials.gov/ct2/show/NCT04441905
Mar 31st, 2023 - A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at one US site. Each subject will be randomized to receive either SAR440894 or matching placebo via 60-minute intravenous infusion. In each cohort of 8 subjects, the randomization ratio will be 6 active to 2 placebo, and 2 sentinel subjects (one fro...
https://clinicaltrials.gov/ct2/show/NCT03506867
Mar 31st, 2023 - Title of Trial: A Healthy People Initiative: A Randomized Controlled Trial Building the Socio-Economic Capital of Low Income Population At-Risk for HIV and Hepatitis-C (HPI Pilot Trial) Short Title of Trial: HPI Pilot Trial Principal Investigator: Smita Pakhalé Trial Sites: Ottawa (The Bridge Engagement Centre) & Toronto (Parkdale Activity Recreation Centre) Primary Objective: To assess the fea...
https://clinicaltrials.gov/ct2/show/NCT04481373
Mar 31st, 2023 - Poor retention in HIV primary care results in lower rates of HIV viral suppression, higher rates of HIV transmission, and exacerbates racial and ethnic disparities in health outcomes, including survival. To date, there are no interventions that effectively relink and retain PWH in care when they are found outside the HIV clinic. Many persons with HIV infection (PWH) are hospitalized with life-t...
https://clinicaltrials.gov/ct2/show/NCT04577755
Mar 31st, 2023 - PRIMARY OBJECTIVE: I. To assess the proportion of participants with Kaposi sarcoma (KS) (with or without human immunodeficiency virus [HIV], regardless of previous treatment status) treated with pomalidomide who respond to treatment with a durable response (i.e., response duration of at least one year). SECONDARY OBJECTIVES: I. To measure the overall response rate (ORR) and report 95% confidenc...
https://clinicaltrials.gov/ct2/show/NCT04491877
Mar 31st, 2023 - Study duration per participant is maximum 12 months
https://clinicaltrials.gov/ct2/show/NCT04513314
Mar 31st, 2023 - This is a pilot feasibility study involving a randomized, single-blind, controlled comparison scheme examining the efficacy and safety of standard of care (n=10) combined with valproate alone, and in combination with quetiapine (N=10) , in order to reduce the magnitude of agitation associated with COVID 19 delirium as assessed by the RASS scale when weaning from a ventilator, and reduce need fo...
https://clinicaltrials.gov/ct2/show/NCT02840877
Mar 31st, 2023 - A major knowledge gap is the degree to which poor treatment outcomes in alcohol-abusing patients are due to noncompliance alone. Problem alcohol use impacts on retention in care and adherence to daily TB treatment. Poor medication adherence and increased default from TB care have been documented for patients consuming alcohol regularly in several countries. Yet there has been no research to ide...
https://clinicaltrials.gov/ct2/show/NCT02836925
Mar 31st, 2023 - The study includes an antiviral treatment with interferon-free regimen followed by lymphoma restaging; following the end of antiviral treatment patients will be evaluated for sustained virological response and safety parameters every 3 months for 1 year and then every 6 months for 2 years. ORR and vital status will be also evaluated.
https://clinicaltrials.gov/ct2/show/NCT04806789
Mar 31st, 2023 - Background: The historical dogma that acute appendicitis always progresses to gangrene and perforation has been rejected. In addition, there is evolving evidence that medical treatment of non-perforated acute appendicitis is safe. On the other hand, perforated acute appendicitis requires appendectomy [Andersson]. Therefore, it is important to differentiate perforation from non-perforation in or...
https://clinicaltrials.gov/ct2/show/NCT04067661
Mar 31st, 2023 - Transgender women (trans women; individuals with a feminine and/or female gender identity who were assigned male at birth) are disproportionately affected by HIV. One of the most consistently reported contexts for HIV transmission among trans women is within a primary partnership. In this partnership context, trans women report low condom use, difficulty disclosing their HIV status and negotiat...
https://clinicaltrials.gov/ct2/show/NCT04872738
Mar 31st, 2023 - Hypothesis 1: Patients will choose to receive the vaccine on the arm contralateral to axillary lymph node removal, or in the lower extremity if they have had bilateral axillary lymph node removal Hypothesis 2: Patients with a history of breast cancer will experience axillary lymph node swelling after receiving the COVID-19 vaccine at the same rate as the general population Hypothesis 3: Patient...
https://clinicaltrials.gov/ct2/show/NCT04960397
Mar 31st, 2023 - This is a Phase 1b, randomized, double-blind, dose-escalating, age de-escalating, placebo-controlled study of 200 children, ages 6 months to 17 years. This clinical trial is designed to assess the safety, tolerability/reactogenicity, and immunogenicity of one and two doses of Sing2016 M2SR H3N2 influenza vaccine (manufactured by FluGen) administered intranasally in seven cohorts of children. Th...
https://clinicaltrials.gov/ct2/show/NCT03183141
Mar 31st, 2023 - Cohort 1 is an open-label extension of study SERES-012. Subjects who had a CDI recurrence in study SERES-012 within 8 weeks of receipt of study drug, have responded to a course of standard of care (SOC) antibiotic treatment, will receive an oral dose of SER-109. A treatment regimen of SER-109 is defined as an oral dose of SER-109 (4 capsules once daily) for 3 consecutive days. Approximately 30 ...
https://clinicaltrials.gov/ct2/show/NCT04031833
Mar 31st, 2023 - Cryptococcal meningitis has emerged as one of the most frequent and deadly opportunistic infections in HIV patients. Historically, amphotericin B (AMB) has been considered the "gold standard" in antifungal treatments due to its broad spectrum of activity and lack of emergence of resistance. However, the use of AMB is limited by side effects, including nephrotoxicity, anemia, and infusion-relate...
https://clinicaltrials.gov/ct2/show/NCT04129177
Mar 31st, 2023 - Surgical location infection (ILQ) is the most frequent complication of surgery and an important source of clinical and economic problems for health systems. The reduction of its incidence is important because of its impact on patient comfort and the health resources used. The ILQ includes the categories of: superficial incisional (IIS, affects skin and subcutaneous tissue); deep incisional (IIP...
https://clinicaltrials.gov/ct2/show/NCT04125784
Mar 31st, 2023 - Background: In developed countries, an increase in cardiovascular events and related mortality has been seen; even more prominent in people living with HIV (PLWHIV) as compared to non-HIV control groups. Studies have shown dyslipidaemia and diabetes mellitus type 2 as important risk factors for cardiovascular diseases in PLWHIV. The original study by this group in 2014 was a cross sectional stu...
https://clinicaltrials.gov/ct2/show/NCT04084444
Mar 31st, 2023 - This is a multicenter, randomized, double-blind, dose-finding, placebo-controlled study in patients with chronic HIV infection and inadequate immune restoration treated with long-term highly active antiretroviral therapy (HAART). A total of 150 eligible subjects will be selected and randomized at a ratio of 1:1:1 into T8 0.5 mg QD, 1 mg QD, and placebo group, with background HAART unchanged, fo...
https://clinicaltrials.gov/ct2/show/NCT04081636
Mar 31st, 2023 - There are two ways to take biopsy (tissue) samples from the prostate. The more commonly used method is trans-rectal needle biopsy of the prostate (TR-Bx) with a needle inserted through a probe in the rectum to reach the prostate. TR-Bx is usually performed in the office, using local anesthesia, and often using a targeted biopsy approach using MRI/ultrasound fusion technique. Trans-perineal biop...
